Raptor, Universite Laval deal

Raptor received exclusive rights to technology from the university related to the use of cysteamine and related compounds to treat Parkinson's disease. According to research done at the university, cystamine (an oxidized form of cysteamine) showed signs of preventing neuron loss and rescuing neurons undergoing a degenerative process in preclinical PD models. The company plans to start a Phase II trial of cysteamine, but did not disclose a timeline. Details were not disclosed. ...